Propranolol Hydrochloride + EtizolamThird Party Manufacturing in India

Propranolol Hydrochloride plus Etizolam combines a non-selective beta-blocker with a thienodiazepine anxiolytic to deliver a unique dual-mechanism approach to anxiety management. Propranolol acts as a competitive antagonist at beta-1 and beta-2 adrenergic receptors. Beta-1 blockade in cardiac tissue reduces heart rate, contractility, and conduction velocity, directly countering the cardiovascular manifestations of anxiety. Beta-2 blockade attenuates peripheral tremor and vasodilation associated with sympathetic activation. Propranolol's central nervous system penetration is significant due to its high lipophilicity, allowing it to modulate adrenergic signalling in the locus coeruleus, hippocampus, and prefrontal cortex, which reduces the cognitive hyperarousal characteristic of anxiety disorders. Etizolam, a thienodiazepine derivative, binds to the benzodiazepine site of the GABA-A receptor complex. Unlike classical benzodiazepines, etizolam contains a thiophene ring instead of a benzene ring, giving it a distinct pharmacological profile with potent anxiolytic properties and relatively milder sedation compared to equianxiolytic doses of diazepam. Etizolam potentiates GABA-mediated inhibitory neurotransmission by increasing the frequency of chloride channel opening. The combination is particularly effective because propranolol reduces the somatic symptoms that can trigger or worsen anxiety, while etizolam provides rapid central anxiolysis with a favourable tolerability profile.

Therapeutic Uses

Propranolol Hydrochloride + Etizolam combination is prescribed for:

• Anxiety Disorders with Prominent Somatic Features: The combination is especially valuable in patients with generalised anxiety disorder where physical symptoms such as palpitations, tremors, and tension headaches are a major component of the clinical presentation. Propranolol targets these somatic symptoms while etizolam provides central anxiolytic effects.

• Panic Disorder: For patients experiencing panic attacks with intense physical sensations including tachycardia and hyperventilation, the beta-blocker component helps break the cycle of physical symptom amplification while etizolam reduces the acute anxiety.

• Situational and Performance Anxiety: The combination is used in patients requiring situational anxiety relief where both psychological apprehension and physical manifestations such as voice tremor and sweating impair performance.

• Essential Tremor Exacerbated by Anxiety: Propranolol is established as a first-line treatment for essential tremor, and the addition of etizolam provides relief from the anxiety that frequently accompanies and worsens this movement disorder.

• Adjustment Disorder with Mixed Anxiety Features: In patients experiencing anxiety symptoms triggered by identifiable stressors, the combination offers rapid symptom relief while addressing both emotional and physiological components.

Why Manufacturers Choose Propranolol Hydrochloride + Etizolam

The Propranolol + Etizolam combination is a specialised anxiolytic formulation that occupies a distinct position in the Indian CNS pharmaceutical market. Etizolam is one of the most widely prescribed anxiolytics in India due to its favourable efficacy-tolerability profile, and its combination with propranolol creates a differentiated product for PCD franchise distribution. Indian manufacturers benefit from the well-established supply chain for both APIs and the relatively simple tablet manufacturing process. The combination is available in multiple strengths, allowing product line expansion for contract manufacturing partners. With growing awareness of anxiety disorders and increasing healthcare-seeking behaviour in India, this combination offers manufacturers steady demand from both domestic and export markets. Third-party manufacturing partners appreciate the consistent prescription volumes and the opportunity to offer a unique combination not widely available from larger competitors.